Amgen (AMGN)
(Delayed Data from NSDQ)
$322.49 USD
-2.20 (-0.68%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $321.50 -0.99 (-0.31%) 6:36 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
AMGN 322.49 -2.20(-0.68%)
Will AMGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMGN
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
AMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Other News for AMGN
Amgen’s Stock Poised for Growth: Solid Financials and Promising Clinical Updates Underpin Buy Rating
Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks
Amgen Hold Rating Justified by Mixed Financial Results, Pipeline Uncertainties, and Competitive Challenges
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Amgen (AMGN) and ACADIA Pharmaceuticals (ACAD)
Amgen Faces Financial Headwinds: Sell Rating Justified Amid Patent Losses and Underwhelming Product Performance